Integrating cure and care in Alzheimer's disease: a systems perspective for precision medicine.
7 affiliations
- 1International Neurodegenerative Disorders Research Center (INDRC.cz), Prague, Czechia.
- 2Akadimi Foundation, Minneapolis, MN, United States.
- 3Arthur J. Gallagher & Co., Rolling Meadows, IL, United States.
- 4Institute for Technology and Medical Systems, Alfred E. Mann Department of Biomedical Engineering, Viterbi School of Engineering & Keck School of Medicine, University of Southern California, Los Angeles, CA, United States.
- 5Center for Artificial Intelligence and Quantum Computing in System Brain Research, International Neurodegenerative Disorders Research Center, Praha, Czechia.
- 6Brain Watch Coalition, Las Vegas, NV, United States.
- 7Campaign to Prevent Alzheimer's Disease, Potomac, MD, United States.
Abstract
Alzheimer's disease remains a major global health challenge, with limited disease-modifying therapies and a rapidly growing societal burden. Although amyloid and tau remain central to the field, current evidence also implicates neuroinflammation, immune dysregulation, vascular dysfunction, and host-microbe interactions in disease pathogenesis. These developments support a broader systems framework, but simply combining additional disciplines or data modalities does not by itself preserve the dynamic biology or lived experience of disease. Artificial intelligence multi-omics, and digital biomarkers can help identify clinically meaningful patterns only when data and models preserve relevant structure across time, scale, context, and uncertainty. Realizing this potential will require responsible international data sharing, interoperable infrastructure, explicit evidence provenance, and ethical governance grounded in FAIR principles, context-appropriate explainability, and privacy-preserving approaches such as federated learning. Scientific progress should therefore be measured not only by disease modification, but also by patterns of cognition, behavior, function, quality of life, and caregiver burden. This Perspective argues that cure and care are not competing or merely parallel priorities; they are linked outputs of the same continuously learning research and care ecosystem.
Related
- AI-bioinformatics synergy for precision medicine in brain diseases: integrating radiomics and multi-omics data.
- Emerging molecular and cellular therapeutics for type 2 diabetes: integrating stem cell and miRNA approaches toward precision medicine.
- Precision Medicine in Acute Coronary Syndromes: Integrating Plaque Phenotyping, Personalized Revascularization, Antithrombotic Strategies, and Residual Risk Reduction
- Integrating the gut microbiome into therapeutic drug monitoring and model-informed precision dosing: a clinical pharmacy perspective
- Digitalized “preventive treatment” in chronic disease control and proactive health: a perspective on integrating TCM wisdom with digital intelligence
BibTeX
@article{rice2026integrating,
title = {{Integrating cure and care in Alzheimer's disease: a systems perspective for precision medicine.}},
author = {James Arthur Rice and Jean-Marie C Bouteiller and Ara S Khachaturian},
journal = {Frontiers in molecular medicine},
year = {2026},
month = oct,
doi = {10.3389/fmmed.2026.1960763},
url = {https://europepmc.org/article/MED/42948807},
note = {CC BY},
}
RIS
TY - JOUR
TI - Integrating cure and care in Alzheimer's disease: a systems perspective for precision medicine.
AU - James Arthur Rice
AU - Jean-Marie C Bouteiller
AU - Ara S Khachaturian
PY - 2026
DA - 2026/10/14
JO - Frontiers in molecular medicine
DO - 10.3389/fmmed.2026.1960763
UR - https://europepmc.org/article/MED/42948807
AB - Alzheimer's disease remains a major global health challenge, with limited disease-modifying therapies and a rapidly growing societal burden. Although amyloid and tau remain central to the field, current evidence also implicates neuroinflammation, immune dysregulation, vascular dysfunction, and host-microbe interactions in disease pathogenesis. These developments support a broader systems framework, but simply combining additional disciplines or data modalities does not by itself preserve the dynamic biology or lived experience of disease. Artificial intelligence multi-omics, and digital biomarkers can help identify clinically meaningful patterns only when data and models preserve relevant structure across time, scale, context, and uncertainty. Realizing this potential will require responsible international data sharing, interoperable infrastructure, explicit evidence provenance, and ethical governance grounded in FAIR principles, context-appropriate explainability, and privacy-preserving approaches such as federated learning. Scientific progress should therefore be measured not only by disease modification, but also by patterns of cognition, behavior, function, quality of life, and caregiver burden. This Perspective argues that cure and care are not competing or merely parallel priorities; they are linked outputs of the same continuously learning research and care ecosystem.
SN - 2674-0095
ER -